Related Experiment Video
Updated: Jul 14, 2026

Optimized Protocol for the Extraction of Proteins from the Human Mitral Valve
Published on: June 14, 2017
Mendelian randomization reveals interactions of the blood proteome and immunome in mitral valve prolapse
Louis-Hippolyte Minvielle Moncla1, Mewen Briend1, Mame Sokhna Sylla1
1Genomic Medicine Laboratory, Quebec Heart and Lung Institute, Laval University, Quebec City, QC, Canada.
Background:
Mitral valve prolapse (MVP) is a common heart disorder characterized by an excessive production of proteoglycans and extracellular matrix in mitral valve leaflets. Large-scale genome-wide association study (GWAS) underlined that MVP is heritable. The molecular underpinnings of the disease remain largely unknown.
Methods:
We interrogated cross-modality data totaling more than 500,000 subjects including GWAS, 4809 molecules of the blood proteome, and genome-wide expression of mitral valves to identify candidate drivers of MVP. Data were investigated through Mendelian randomization, network analysis, ligand-receptor inference and digital cell quantification.
Results:
In this study, Mendelian randomization identify that 33 blood proteins, enriched in networks for immunity, are associated with the risk of MVP. MVP- associated blood proteins are enriched in ligands for which their cognate receptors are differentially expressed in mitral valve leaflets during MVP and enriched in cardiac endothelial cells and macrophages. MVP-associated blood proteins are involved in the renewal-polarization of macrophages and regulation of adaptive immune response. Cytokine activity profiling and digital cell quantification show in MVP a shift toward cytokine signature promoting M2 macrophage polarization. Assessment of druggability identify CSF1R, CX3CR1, CCR6, IL33, MMP8, ENPEP and angiotensin receptors as actionable targets in MVP.
Conclusions:
Hence, integrative analysis identifies networks of candidate molecules and cells involved in immune control and remodeling of the extracellular matrix, which drive the risk of MVP.
Insights
Mitral valve prolapse (MVP) involves immune system proteins linked to macrophage changes. This study identifies key blood proteins and cellular pathways driving MVP risk and potential drug targets.
Area of Science:
- Cardiovascular Genetics
- Immunology
- Proteomics
Background:
- Mitral valve prolapse (MVP) is a common, heritable heart disorder.
- Characterized by excessive proteoglycans and extracellular matrix in valve leaflets.
- Molecular causes of MVP remain largely unknown.
Purpose of the Study:
- Identify molecular drivers of Mitral Valve Prolapse (MVP).
- Investigate genetic and molecular underpinnings of MVP heritability.
- Explore immune system involvement in MVP pathogenesis.
Main Methods:
- Integrated analysis of Genome-Wide Association Studies (GWAS), blood proteome, and mitral valve gene expression data.
- Utilized Mendelian randomization, network analysis, and ligand-receptor inference.
- Employed digital cell quantification and cytokine profiling.
Main Results:
- Identified 33 blood proteins associated with MVP risk, enriched in immune networks.
- MVP-associated proteins link to receptors on cardiac endothelial cells and macrophages.
- Observed a shift towards M2 macrophage polarization in MVP, suggesting immune dysregulation.
- Highlighted CSF1R, CX3CR1, CCR6, IL33, MMP8, ENPEP, and angiotensin receptors as potential therapeutic targets.
Conclusions:
- Integrative analysis reveals immune control networks driving MVP risk.
- Extracellular matrix remodeling is implicated in MVP pathogenesis.
- Identified specific cellular and molecular targets for MVP intervention.
More Related Videos
Related Concept Videos
Mitral Valve Prolapse I: Introduction
Mitral Valve Prolapse II: Assessment and Management
Mitral Valve Prolapse III: Nursing Management
Mitral Regurgitation I: Introduction
Mitral Stenosis I: Introduction

